CTNNB1 and hepatoblastoma: Genomic studies have revealed a remarkably low tumor mutational burden, with up to 80–90% of hepatoblastomas containing mutations of the CTNNB1 gene that abrogate degradation of the β-catenin protein, leading to constitutive activation of the Wnt pathway11–15.